Evidence map›Paper›PMID 41502679›Full record

ArticleACS omega2025

Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation.

Ana Rs Ribeiro, Ander Eguskiza, Hieu-Hoa Dang, Theresa Neuper, Michael Stefan Unger, Laura Rodriguez Comas, Markus Steiner, Helene Sieberer, Nadja Zaborsky, Richard Greil and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ana Rs RibeiroDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Hellbrunner Str 34, Salzburg 5020, Austria.
Ander EguskizaDepartment of Biotechnology, University of Verona, Strade Le Grazie 15, Verona 37134, Italy.
Hieu-Hoa DangDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Hellbrunner Str 34, Salzburg 5020, Austria.
Theresa NeuperDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Hellbrunner Str 34, Salzburg 5020, Austria.
Michael Stefan UngerDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Hellbrunner Str 34, Salzburg 5020, Austria.
Laura Rodriguez ComasDepartment of Molecules and Materials, TechMed Centre and MESA+ Institute, University of Twente, Drienerlolaan 5, Enschede 7500 AE, The Netherlands.
Markus SteinerCancer Cluster Salzburg (CCS), Hellbrunner Str 34, Salzburg 5020, Austria.ORCID https://orcid.org/0000-0003-4424-6347
Helene SiebererDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Hellbrunner Str 34, Salzburg 5020, Austria.
Nadja ZaborskyCancer Cluster Salzburg (CCS), Hellbrunner Str 34, Salzburg 5020, Austria.
Richard GreilCancer Cluster Salzburg (CCS), Hellbrunner Str 34, Salzburg 5020, Austria.
Mireia Vilar I HernandezDepartment of Molecules and Materials, TechMed Centre and MESA+ Institute, University of Twente, Drienerlolaan 5, Enschede 7500 AE, The Netherlands.ORCID https://orcid.org/0000-0002-8303-9060
Pascal JonkheijmDepartment of Molecules and Materials, TechMed Centre and MESA+ Institute, University of Twente, Drienerlolaan 5, Enschede 7500 AE, The Netherlands.ORCID https://orcid.org/0000-0001-6271-0049
Roberto FiammengoDepartment of Biotechnology, University of Verona, Strade Le Grazie 15, Verona 37134, Italy.ORCID https://orcid.org/0000-0002-6087-6851
Jutta Horejs-HoeckDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Hellbrunner Str 34, Salzburg 5020, Austria.ORCID https://orcid.org/0000-0002-0984-204X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of the STING pathway is crucial for antitumor immunity, but targeting the STING receptor therapeutically remains a challenge due to inefficient intracellular delivery of its agonists. Here, we explore the potential of FDA-approved lipid nanoparticles (LNPs), used in Spikevax COVID-19 vaccine, to increase the uptake of a cGAMP analog (cG

Identifiers

PMID41502679
PMCPMC12771213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.